AMENDMENT #2 Compound Pharmaceuticals for Dept of Pharmacy, Carl R. Darnall Army Medical Center, Fort Hood, Tx.

This government solicitation, W81K0026QA064, is for Women-Owned Small Businesses (WOSB) to provide compound pharmaceuticals for the period of April 1, 2026, to September 30, 2030. The contract, issued by W81K00 and administered by W40M MRC0 WEST, JBSA Ft Sam Houston, TX, includes specific items such as Succinylcholine, L.E.T., Phenylephrine, and Oxytocin in NS. The solicitation outlines delivery to AMC Hood - PA in Fort Hood, TX, with the contractor responsible for transportation costs. Key clauses include those related to Item Unique Identification and Valuation, and Wide Area WorkFlow Payment Instructions, ensuring compliance with federal acquisition regulations and Department of Defense financial procedures. Offerors must complete sections including pricing, contractor information, and signing the document.

This amendment to solicitation W81K0026QA0640001 outlines significant changes for contractors, primarily focusing on subcontractor responsibilities and proposal submission requirements for compound pharmaceuticals. Key updates include the addition of FAR Clause 52.244-2, Subcontracts, which establishes the prime contractor as the single point of responsibility for the entire contract, holding them liable for subcontractor actions. Furthermore, it mandates that all requirements must be met by a single entity—either the prime or a single subcontractor—prohibiting combined capabilities. Offerors utilizing subcontractors must submit executed Teaming Agreements detailing roles and work allocation; failure to do so will result in proposal non-responsiveness. The solicitation also removes the "Subject to Availability of Funds" language from CLIN 0001, indicating committed funding. The evaluation criteria emphasize a Lowest Price Technically Acceptable (LPTA) approach, requiring offerors to provide the entirety of the requested compound pharmaceuticals and meet specific certifications (FDA or PCAB), quality control, and delivery standards. Questions are due by February 3, 2026, and quotes by February 5, 2026, both via email.

This document is an amendment to solicitation W81K0026QA064, issued by the Medical Readiness Contracting Office West, updating the terms and conditions for providing compounded pharmaceuticals. The amendment, dated February 4, 2026, includes a critical Q&A section clarifying the prescription process for compounded drugs in government medical facilities. It specifies that for inpatient pharmacy settings and emergency departments, prescriptions are not required; instead, medication orders and authorizations from providers are used, billed as inpatient medical expenses. This practice is consistent with other Military Treatment Facilities (MTFs) and CRDAMC's existing procedures. All other terms of the original solicitation remain unchanged.